GU Cancers Symposium 2012 - Approved agents and related trials - Session Highlights

SAN FRANCISCO, CA, USA ( - Dr. Gary MacVicar challenged the GU Symposium audience to effectively sequence, combine therapies, and target treatments to men with metastatic CRPC.

After years where doxetaxel was the go-to agent, now there are FDA-approved agents to treat mCRPC with strong phase III trial data to support improved survivability (Sipuleucel-T, cabazitaxel, and abiraterone). Radium-223 is demonstrating strong clinical data. Denosumab, an option to delay progression of bone disease in men with M0 CRPC, is a monoclonal antibody agent, and in initial studies has proved to disrupt that vicious cycle of bone targeted therapy and with lower toxicity levels. Dr. MacVicar notes the need to include a calcium supplement with vitamin D for those patients on denosumab.

In all the therapeutic categories (immunotherapy, hormonal therapy, targeted bone therapy, and cytotoxic chemotherapy) more studies are needed to identify how to best sequence or combine these novel agents along with how to select therapies for individual patients or subsets of patients.


Median Survival Benefit
Hazard Ratio
P Value
TAX 327 Docetaxel/prednisone vs. mitoxantrone/prednisone 1,006 2.4 0.76 0.009
IMPACT Sipuleucel-T vs. placebo 512 4.1 0.775 0.032
TROPIC Cabazitaxel/prednisone vs. mitoxantrone/prednisone 755 2.4 0.70 <0.0001
COU 301 Abiraterone/prednisone vs. placebo/prednisone 1,195 3.9 0.65 < 0.001
ALSYMPCA Radium-223 vs. placebo 922 2.8 0.695 0.00185

Phase III trials with improvements in overall survival in metastatic castration-resistant prostate cancer



Presented by Gary R. MacVicar, MD at the 2012 Genitourinary Cancers Symposium - February 2 - 4, 2012 - San Francisco Marriott Marquis - San Francisco, California
Northwestern University, Chicago, IL

Reported for UroToday by Karen Roberts, Medical Writer



View Full 2012 GU Cancers Symposium Coverage